The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality
worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new …

Improvements in early detection and treatment have led to a growing prevalence of survivors
of cancer worldwide. Models of care fail to address adequately the breadth of physical …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Background The development of immune checkpoint inhibitors (ICIs) represents a paradigm
shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved cancer outcomes.
However, immune-related adverse effects are common. The aim was to investigate the …

Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced
cancer and have emerged as a pillar of standard cancer care. However, their use is …

Importance For patients with advanced non–small cell lung cancer (NSCLC) treated with
frontline immunotherapy-based treatment, the optimal duration of immune checkpoint …

Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis
and clinical staging of hepatocellular carcinoma (HCC). We have published the first version …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …